- Camrelizumab combined with lenvatinib and RALOX-HAIC for hepatocellular carcinoma (HCC) in BCLC stage B and C: A prospective, single-arm, phase II trial (Cal Era study)Zang, M.; Li, Q.; Pang, H.; Hu, X.; Li, R.; Yuan, G.; Li, W.; Guo, Y.; Chen, J.Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), ELECTR NETWORK, 2022-09-09 To 2022-09-13.
- Camrelizumab (C) plus rivoceranib (R) vs. sorafenib (S) as first-line therapy for unresectable hepatocellular carcinoma (uHCC): A randomized, phase III trialQin, S.; Chan, L. S.; Gu, S.; Bai, Y.; Ren, Z.; Lin, X.; Chen, Z.; Jia, W.; Jin, Y.; Guo, Y.; Sultanbaev, A. V.; Pazgan-Simon, M.; Pisetska, M.; Liang, X.; Chen, C.; Nie, Z.; Wang, L.; Cheng, A-L.; Kaseb, A.; Vogel, A.Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), ELECTR NETWORK, 2022-09-09 To 2022-09-13.被引 85
- The efficacy and safety of cadonilimab combined with lenvatinib for first-line treatment of advanced hepatocellular carcinoma: A phase Ib/II clinical trialBai, L.; Bai, Y.; Huang, M.; Shao, G.; Song, L.; Sun, M.; Wang, W.; Wu, J.; Xu, A.; Huang, L.; Liu, T.; Liu, W.; Wang, Z. M.; Li, B.; Xia, Y.Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), Barcelona, SPAIN, 2023-10-20 To 2023-10-24.
会议论文
Camrelizumab combined with lenvatinib and RALOX-HAIC for hepatocellular carcinoma (HCC) in BCLC stage B and C: A prospective, single-arm, phase II trial (Cal Era study)
1被引11阅读
